Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
TM4SF19-DYNLT2B is a naturally occurring read-through transcript between TM4SF19 and DYNLT2B on chromosome 3, generally subject to nonsense-mediated mRNA decay and is not expected to produce a protein product. No biological function or disease involvement as a protein or target has been demonstrated. Occasionally, rare associations with specific rare syndromes may arise through linked genetic variation, but this transcript itself is not an actionable target for drugs or diagnostics[1][9].
None (not a drug target)
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on TM4SF19-DYNLT2B readthrough (TM4SF19-DYNLT2B).